Hiroshi Onogi, MD
Executive Vice President, Head of Clinical Development – Japan

Dr. Onogi oversees all clinical development in Japan and is also responsible for liaising with the PMDA. He has more than 20 years of experience and brings a wealth of diversified experience to this role, which includes extensive expertise in new oncology drug development, from early stage to NDA and safety. Read More >

Ken Nanami
Director, Clinical Operations

Mr. Nanami is responsible for managing clinical studies in Japan including the two ongoing, registration clinical studies in Japan in PTCL and ATL. Prior to joining HUYA he worked on major projects at Pfizer Japan Inc., Schering-Plough K.K., Allergan Japan K.K. and Galderma K.K. and also has experience with cervical cancer studies at Zeria Pharmaceutical Co., Ltd. Read More >

Yukitaka Takatsu

Yukitaka Takatsu
Director, Clinical Operations

Mr. Takatsu is responsible for clinical operations contributing to the successful execution of ongoing clinical registration studies in Japan for both PTCL and ATL. Mr. Takatsu has worked for a number of pharmaceutical companies, including Nippon Roche, Nippon Mining, Nippon Organon, Abbott Japan and Covance Japan and has an accumulation of over 35 years of senior management experience which has included clinical development experience at a senior level across a number of therapeutic fields. Read More >

Masutoshi Toya

Masutoshi Toya
Clinical Project Management Director

Masutoshi Toya is responsible for project managing the HBI-8000 clinical trials in Japan and subsequent regulatory activity. He is responsible for ensuring that all project timeline and milestones are met for these important registration studies. Read More >

Yukari Hayakawa

Yukari Hayakawa
Director, Administration

Ms. Hayakawa provides general administrative support for all of HUYA’s operations in Japan. She has more than 10 years’ experience in the industry and is recognized as having significant expertise as an Executive Assistant serving senior executives and managers in multi-national companies in a cross-cultural environment. Read More >